Title | Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy. |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Bagnato F, Gauthier SA, Laule C, Moore GRWayne, Bove R, Cai Z, Cohen-Adad J, Harrison DM, Klawiter EC, Morrow SA, Öz G, Rooney WD, Smith SA, Calabresi PA, Henry RG, Oh J, Ontaneda D, Pelletier D, Reich DS, Shinohara RT, Sicotte NL |
Corporate Authors | NAIMS Cooperative |
Journal | J Neuroimaging |
Volume | 30 |
Issue | 3 |
Pagination | 251-266 |
Date Published | 2020 May |
ISSN | 1552-6569 |
Keywords | Atrophy, Brain, Disease Progression, Humans, Magnetic Resonance Imaging, Multiple Sclerosis, Positron-Emission Tomography, Spinal Cord |
Abstract | Clinicians involved with different aspects of the care of persons with multiple sclerosis (MS) and scientists with expertise on clinical and imaging techniques convened in Dallas, TX, USA on February 27, 2019 at a North American Imaging in Multiple Sclerosis Cooperative workshop meeting. The aim of the workshop was to discuss cardinal pathobiological mechanisms implicated in the progression of MS and novel imaging techniques, beyond brain atrophy, to unravel these pathologies. Indeed, although brain volume assessment demonstrates changes linked to disease progression, identifying the biological mechanisms leading up to that volume loss are key for understanding disease mechanisms. To this end, the workshop focused on the application of advanced magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging techniques to assess and measure disease progression in both the brain and the spinal cord. Clinical translation of quantitative MRI was recognized as of vital importance, although the need to maintain a relatively short acquisition time mandated by most radiology departments remains the major obstacle toward this effort. Regarding PET, the panel agreed upon its utility to identify ongoing pathological processes. However, due to costs, required expertise, and the use of ionizing radiation, PET was not considered to be a viable option for ongoing care of persons with MS. Collaborative efforts fostering robust study designs and imaging technique standardization across scanners and centers are needed to unravel disease mechanisms leading to progression and discovering medications halting neurodegeneration and/or promoting repair. |
DOI | 10.1111/jon.12700 |
Alternate Journal | J Neuroimaging |
PubMed ID | 32418324 |
Grant List | R01 NS082347 / NH / NIH HHS / United States R01 NS080816 / NH / NIH HHS / United States CA TA 3062-A-3 / / National Multiple Sclerosis Society / International R01 MH112847 / NH / NIH HHS / United States RO1 NS109114-01 / NH / NIH HHS / United States K01 EB023312 / NH / NIH HHS / United States FDN‐143263 / / CIHR / Canada P41 EB015894 / NH / NIH HHS / United States P30 NS076408 / NS / NINDS NIH HHS / United States R01 NS090464 / NH / NIH HHS / United States K23NS078044 / NH / NIH HHS / United States RG 1807-31051 / / National Multiple Sclerosis Society / International R21NS106522 / NH / NIH HHS / United States RO1 NS104283 / NH / NIH HHS / United States 1R01NS104403-01 / NH / NIH HHS / United States R01 NS060910 / NH / NIH HHS / United States R01-EB007258 / NH / NIH HHS / United States R01 NS091683 / NH / NIH HHS / United States R01 NS085211 / NH / NIH HHS / United States R01NS40801 / NH / NIH HHS / United States R01 AG058773 / NH / NIH HHS / United States R01NS109114-01 / NH / NIH HHS / United States R01NS104149 / NH / NIH HHS / United States R37NS041435 / NH / NIH HHS / United States L30 NS088825 / NS / NINDS NIH HHS / United States RO1 NS105144 / NH / NIH HHS / United States R01 NS104283 / NS / NINDS NIH HHS / United States |